Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 8:40 AM ET. The company is a clinical-stage oncology therapeutics firm focused on antibody drug conjugates (ADC).

A live webcast will be available via the company's investor relations website and will be replayable for approximately 30 days after the presentation.

News Market Reaction – WHWK

+2.04%

1 alert

+2.04% News Effect

On the day this news was published, WHWK gained 2.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $2.94 52-week range: $1.39–$3.7699 Cash & investments: $162.6M +5 more

8 metrics

Current price $2.94 Pre-news price for WHWK

52-week range $1.39–$3.7699 52-week low and high for WHWK

Cash & investments $162.6M As of Sept 30, 2025 (Q3 2025 10-Q)

Q3 2025 net loss $17.7M Quarter ended Sept 30, 2025

Stock options granted 650,000 shares at $2.26 CMO equity grant on Dec 1, 2025 (Form 4)

RSUs granted 55,309 RSUs CMO equity grant on Dec 1, 2025 (Form 4)

Beneficial ownership 2,819,215 shares (5.98%) Coastlands Schedule 13G as of Aug 4, 2025

Shares outstanding 47,128,362 As of Nov 4, 2025 (10-Q)

Market Reality Check

Price: $3.51 Vol: Volume 40,025 vs 20-day a...

low vol

$3.51 Last Close

Volume Volume 40,025 vs 20-day avg 113,027 (relative volume 0.35). low

Technical Price $2.94 trading above 200-day MA at $2.12, showing pre-news upward bias.

Peers on Argus

Peers show mixed moves: IF RX, PTHS, SRZN down, IPA up, ORMP flat. No broad biot...

1 Up

Peers show mixed moves: IF RX, PTHS, SRZN down, IPA up, ORMP flat. No broad biotech move aligned with WHWK’s modest 3.16% gain.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	IND clearance update	Positive	+1.5%	FDA IND clearance for HWK-007 and IND submission for HWK-016.
Dec 01	Executive appointment	Positive	-3.4%	Appointment of experienced oncology CMO Margaret Dugan, MD.
Nov 26	Conference participation	Neutral	+7.0%	Participation in Piper Sandler healthcare conference with webcast access.
Nov 11	Conference presentation	Neutral	+2.3%	Jefferies Global Healthcare Conference presentation with 30-day replay.
Nov 06	Quarterly earnings	Neutral	-6.7%	Q3 2025 financials with higher cash balance and wider net loss.

Pattern Detected

News has generally led to aligned reactions, with positive clinical/strategic updates often followed by modest gains and one divergence on a management hire.

Recent Company History

Over the past few months, Whitehawk progressed from balance-sheet strengthening to clinical execution. The Nov 6, 2025 Q3 update highlighted $162.6M in cash and a larger net loss, followed by multiple conference appearances in November and December 2025. On Jan 8, 2026, IND clearance for HWK-007 and an IND filing for HWK-016 moved the company into the clinical stage. Today’s Oppenheimer conference presentation continues this pattern of investor outreach as clinical programs advance.

Market Pulse Summary

This announcement highlights Whitehawk’s participation in a major healthcare conference on February ...

Analysis

This announcement highlights Whitehawk’s participation in a major healthcare conference on February 25, 2026, continuing a series of investor-facing events following its transition to a clinical-stage ADC company. Recent history includes IND clearance for HWK-007 and an IND filing for HWK-016, plus a Q3 2025 cash position of $162.6M. Investors may watch for any new clinical detail, partnering commentary, or updated cash runway metrics discussed during the presentation.

Key Terms

antibody drug conjugate, adc

2 terms

antibody drug conjugate medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.

adc medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

AI-generated analysis. Not financial advice.

MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.

A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-302691346.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

When will Whitehawk Therapeutics (WHWK) present at the Oppenheimer conference?

Whitehawk Therapeutics will present on February 25, 2026 at 8:40 AM ET. According to the company, Dave Lennon, PhD, President and CEO, will deliver the presentation at that scheduled time.

How can investors watch the WHWK presentation at Oppenheimer on February 25, 2026?

Investors can watch a live webcast via Whitehawk Therapeutics' investor relations website. According to the company, the webcast will also be available for replay for about 30 days after the event.

Who is presenting for Whitehawk Therapeutics (WHWK) at the Oppenheimer 2026 conference?

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, will present at the conference. According to the company, he will represent the clinical-stage oncology firm during the session.

What topics will Whitehawk Therapeutics (WHWK) likely cover in the Oppenheimer conference presentation?

The presentation will focus on Whitehawk's clinical-stage oncology work and antibody drug conjugate (ADC) programs. According to the company, the discussion will center on their ADC approach and clinical development progress.

Will the WHWK Oppenheimer presentation be available after February 25, 2026?

Yes, the presentation replay will be available for approximately 30 days following the event. According to the company, the webcast replay can be accessed via the investor relations website during that period.